HOWARU® Strains Help Support Respiratory Health

Pollution, allergies, and upper respiratory infections caused by viruses such as rhinovirus and coronaviruses like COVID-19* are growing concerns worldwide. Our HOWARU® probiotic solutions that support overall immune health and bolster healthy respiratory function in adults meet our HOWARU® VERIFY protocol. 

*Taking a probiotic does not decrease the risk of getting COVID-19 and is not intended to diagnose, treat, cure, or prevent any disease.

Probiotic supplementation for respiratory and gastrointestinal illness symptoms in healthy physically active individuals.1

Study aim

To determine if daily intake of a formulation containing Bifidobacterium lactis Bl-04® would have a positive impact in the prevention of upper respiratory tract illness (URTI) episodes.

Study design

5-month, double-blind, placebo controlled 

Study method

310 healthy, physically active adults randomized to two treatment groups*:

  • Placebo
  • Bl-04® (2 billion CFU)

*An additional probiotic formula was investigated in this study, but results are not reported here.

Evaluation of symptoms and physical activity were conducted via Web-based questionnaire. The signs and symptoms of URTI included a scratchy throat, sore throat, sneezing, stuffy nose, or runny nose. A diagnosis of URTI was made when two or more symptoms were recorded for three or more consecutive days.

Study results

Bl-04® was associated with decreased risk of URTI episodes
  • Subjects taking Bl-04® had 27% less risk of experiencing URTI episodes compared to placebo (P=0.02)

Effect of probiotic on innate inflammatory response and viral shedding in experimental rhinovirus infection–a randomised controlled trial.2

Study aim

To study the effect of B. lactis Bl-04® on innate and adaptive immune responses, and nasal rhinovirus load for 5 days following a rhinovirus challenge infection.

Study design

Randomized, double-blind, placebo controlled 

Study method

115 healthy adults were randomized to two treatment groups:

  • Placebo
  • Bl-04® (2 billion CFU)
  • All participants challenged with nasal application of rhinovirus

Markers of immune function (interleukin 8 and other cytokines) and rhinovirus levels were measured from nasal washes as well as other endpoints.

Study results

Bl-04® reduced the amount of rhinovirus in nasal mucosa
  • Bl-04® supplementation decreased the amount of rhinovirus in nasal washes during the 5 days following a rhinovirus challenge compared to placebo (P=0.026)

Bibliography

REFERENCES:

1. West NP, Horn PL, Pyne DB, et al. Probiotic supplementation for respiratory and gastrointestinal illness symptoms in healthy physically active individuals. Clin Nutr. 2014;33(4):581-587. 2. Turner RB, Woodfolk JA, Borish L, et al. Effect of probiotic on innate inflammatory response and viral shedding in experimental rhinovirus infection – a randomized controlled trial. Benef Microbes. 2017;8(2):207-215.

When adult patients need immune support, recommend clinically researched HOWARU® strains
The information on this site is intended for healthcare professionals in the United States and is not intended for the general public.
ARE YOU A HEALTHCARE PROFESSIONAL?
YES
NO